Company Overview

Update
Founded:
2007
Founders:
Peter G. Schultz
Headquarters:
Fremont, CA
Funding:
$35M
Categories:
Biotechnology

Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.

Description

Update

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company’s molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The Company’s non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Company’s lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a... See More

Current Team (11)

Update

Board Members and Advisors (2)

Update

Funding Rounds (2) - $35M

Update

Investors (3)

Update

Offices/Locations (1)

Update
  • Office

    34175 Ardenwood Blvd.

    Fremont, CA 94555

    USA

Images (1)

Update
  • Dd117468eb6f9d4438518027e889bff6